isotypic


Also found in: Dictionary, Medical.

isotypic

[¦ī·sə¦tip·ik]
(crystallography)
Pertaining to a crystalline substance whose chemical formula is analogous to, and whose structure is like, that of another specified compound.
References in periodicals archive ?
In contrast to many of our competitors, our understanding and use of our HDAC isotypic compound libraries provides us with the opportunity to investigate HDAC inhibition in non-oncology settings.
For example, if the capture, detection, and infused antibodies are identical, then the assay will detect isotypic and idiotypic HAMAs.
Signed an exclusive research, collaboration and license agreement with EnVivo Pharmaceuticals to exploit MethylGene's isotypic selective HDAC inhibitor technology for the treatment of neurodegenerative diseases.
The MCF with MWH was also associated with a consistent lower background observed with isotypic antibodies or when no primary antibody was added.
These observations and target validation data are important for guiding and developing novel isotypic selective small molecule inhibitors for cancer and other disease indications in MethylGene's research and development portfolio," stated Dr.
To characterize the specificity of the HAMAs insensitive to MAK33 and to clarify how far they are directed against isotypic determinants not expressed on the [gamma.
Initiated two monotherapy, dose escalation, Phase I solid tumour trials with its isotypic selective histone deacetylase (HDAC) enzyme inhibitor, MGCD0103, at sites in Canada and the United States.
MGCD0103 is a rationally designed isotypic selective small molecule inhibitor of histone deacetylase (HDAC).
EnVivo Pharmaceuticals completed a "proof of concept" with a set of the Company's HDAC inhibitors and exercised its option to enter into an exclusive research, collaboration and license agreement to exploit MethylGene's isotypic selective HDAC inhibitor technology in neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's disease.
MGCD0103 is an orally active, isotypic selective, small molecule HDAC inhibitor that inhibits a specific subset of cancer-related HDAC enzymes, resulting in an activity profile that is genotypically, phenotypically and functionally distinct from indiscriminate HDAC inhibitors.
MethylGene's proprietary isotypic selective anti-cancer HDAC inhibitor, MGCD0103, is currently advancing through two Phase I dose-escalation monotherapy clinical trials at sites in Canada and the United States in patients with advanced solid malignancies refractory to currently available therapies.
biopharmaceutical company focusing on the treatment and prevention of neurodegenerative diseases, today announced that EnVivo has exercised its option to enter into an exclusive research, collaboration and license agreement to exploit MethylGene's isotypic selective small molecule histone deacetylases (HDAC) inhibitors for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's disease.